Inflexa and Genomate Health partner to investigate cancer drug response
Pairing computational cohort reasoning with multi-omics analysis to understand why tumors behave differently than their genomes predict
We're glad to share that Inflexa and Genomate Health have begun a research collaboration focused on one of oncology's more stubborn questions: why do some tumors respond to a drug differently than their molecular profile says they should?
A tumor's genome describes what it is capable of. It says much less about what the tumor is actually doing at any given moment, and that gap is often where drug response hides. This collaboration is built to look into it directly, by combining computational reasoning about which patients to study with a close read of the biology inside those cohorts.
The two teams bring complementary halves of the same problem. Genomate defines the cohorts worth looking at; Inflexa reads what the biology is doing inside them.
Genomate Health
Computational reasoning that identifies biologically meaningful patient cohorts from their molecular context, grouping cases by the biology they share rather than by convenience.
Inflexa
Multi-omics analysis across those cohorts, reading transcriptomic, proteomic, and other data layers to surface biological patterns that genomic data alone can miss.
By putting the right cohorts in front of the right analysis, the collaboration aims to surface biomarkers and biological signals that standard, single-layer analysis tends to miss. If the approach holds up, it points toward a repeatable way to study the questions clinicians and researchers care about most.
Exceptional responders
Patients who respond differently than their molecular profile predicts, and what their biology can teach us.
Resistance mechanisms
How and why tumors stop responding to therapies that once worked.
Biomarker discovery
Molecular signatures that help explain response across targeted therapies, traceable back to the data they came from.
This is early, exploratory work, and we'll share what it uncovers as it develops. You can read Genomate Health's announcement of the collaboration here.
Working on cancer drug response?
If you're studying why tumors respond the way they do, we'd love to talk.